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Abstract: Research on vaccines against trypanosomatids, a family of protozoa that cause neglected
tropical diseases, such as Chagas disease, leishmaniasis, and sleeping sickness, is a current need.
Today, according to modern vaccinology, virus-like particle (VLP) technology is involved in many
vaccines, including those undergoing studies related to COVID-19. The potential use of VLPs as
vaccine adjuvants opens an opportunity for the use of protozoan antigens for the development of
vaccines against diseases caused by Trypanosoma cruzi, Leishmania spp., and Trypanosoma brucei. In
this context, it is important to consider the evasion mechanisms of these protozoa in the host and the
antigens involved in the mechanisms of the parasite–host interaction. Thus, the immunostimulatory
properties of VLPs can be part of an important strategy for the development and evaluation of
new vaccines. This work aims to highlight the potential of VLPs as vaccine adjuvants for the
development of immunity in complex diseases, specifically in the context of tropical diseases caused
by trypanosomatids.
Keywords: virus-like particles; vaccine; trypanosomatids; Chagas disease; leishmaniasis; African try-
panosomiasis
1. Introduction
Trypanosoma cruzi, Trypanosoma brucei, and Leishmania spp. are flagellate parasites that
belong to the Trypanosomatidae family and have a complex life cycle between invertebrate
and mammalian hosts, where they cause Chagas disease, African trypanosomiasis, and
leishmaniasis, respectively (Figure 1). These diseases mainly affect economically vulnerable
populations, leading to thousands of annual deaths and major public health problems [1].
To ensure survival during infection, these protozoa have developed sophisticated
evasion mechanisms to circumvent the immune system and virulence factors that facilitate
the maintenance of the parasite–host interaction. Their invasion and embedment in various
tissues lead to the establishment of the chronicity of these diseases. By invading specific
tissues and regions of the body and staying within them, parasites hamper the accessibility
of drugs that are traditionally used to treat these diseases, which leads to low efficiency in
the chronic stage and, in many cases, high toxicity. Therefore, the mammalian inability to
eliminate these parasites efficiently and the lack of adequate treatment require the search
for new technologies to prevent and combat these infectious diseases [2–4].
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Figure 1. Schematic representation of the biological cycle of some trypanosomatids: Trypanosoma 
brucei (lilac), Trypanosoma cruzi (blue), and Leishmania spp. (red). Invertebrate hosts: Phebotomineos 
(P), Triatoma sp. (T), and Glossina sp. (G). The different evolutionary forms of these protozoa are 
represented: bloodstream form (BSF); procyclic form (PCF); metacyclic forms (M); amastigotes (A); 
promastigotes (P); epimastigotes (E); and trypomastigotes (T). 
In this scenario, the development of vaccines to control these infectious diseases, 
despite representing a major challenge from a biotechnological point of view, is an urgent 
need. Due to the biological complexity of these protozoa, characterized mainly by dif-
ferent evolutionary forms, the search for antigenic candidates for the design of vaccine 
prototypes represents a major issue. On the other hand, during the maintenance of the 
infection, these parasites cause immunity response polarization, a phenomenon that 
governs the resistance and susceptibility mechanisms of the infected hosts. Thus, the ap-
plication of technology involving virus-like particles (VLPs) has become an interesting 
tool for the development of vaccines in the context of infections caused by trypanosoma-
tids, since VLPs have the immunoadjuvant ability to manipulate immune response po-
larization [5]. 
VLPs used as vaccine adjuvants provide an alternative to current chemical adju-
vants, along with an ability to carry foreign epitopes; they constitute platforms for the 
development of new prototypes and vaccine protocols. VLPs’ immunostimulatory 
properties are similar to natural infections of the viruses from which they are derived, 
and the preservation of the native conformation is, in addition to the primary sequence, a 
major factor responsible for this property [6,7]. Therefore, parasitic antigens presented to 
the immune system in the context of VLPs (chemical linkage or genetic manipulation) 
represent an interesting biomedical application for the development of state-of-the-art 
vaccines. Thus, the objective of this work is to reflect on the use of VLPs as vaccine ad-
juvants in the context of infections by trypanosomatids of medical importance. 
2. Application of the Use of VLPs in the Development of New Vaccines 
The structural conformation of VLPs mimics the morphology and structures of viral 
particles without the presence of the virus genome, and therefore, they are not infectious 
particles. Thus, the main advantages of using VLPs as vaccine prototypes are safety, since 
they are not infectious viral particles, and the ability to induce a robust immune response 
that is highly similar to that elicited by a natural viral infection. These two characteristics 
allow VLPs to be used in the development of vaccines [8]. 
Additionally, there are several ways to produce recombinant VLPs, mainly using 
gene expression systems in bacteria, yeasts, insect cells, and mammalian cells, among 
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VLPs used as vaccine adjuvants provide an alternative to current chemical adjuvants,
along with an ability to carry foreign epitopes; they constitute platforms for the develop-
ment of new prototypes and vaccine protocols. VLPs’ immunostimulatory properties are
similar to natural infections of the viruses from which they are derived, and the preser-
vation of the native conformation is, in addition to the primary sequence, a major factor
responsible for this property [6,7]. Therefore, parasitic antigens presented to the immune
system in the context of VLPs (chemical linkage or genetic manipulation) represent an
interesting biomedical application for the development of state-of-the-art vaccines. Thus,
the objective of this work is to reflect on the use of VLPs as vaccine adjuvants in the context
of infections by trypanosomatids of medical importance.
2. Application of the Use of VLPs in the Development of New Vaccines
The structural conformation of VLPs mimics the morphology and structures of viral
particles without the presence of the virus genome, and therefore, they are not infectious
particles. Thus, the main advantages of using VLPs as vaccine prototypes are safety, since
they are not infectious viral particles, and the ability to induce a robust immune response
that is highly similar to that elicited by a natural viral infection. These two characteristics
allow VLPs to be used in the development of vaccines [8].
Additionally, there are several ways to produce recombinant VLPs, mainly using gene
expression systems in bacteria, yeasts, insect cells, and mammalian cells, among others [9].
The strategy for the construction and production of recombinant VLPs depends on viral
biology, mainly the presence or absence of a viral envelope, and the choice of the best
system for gene expression and purification of recombinant particles [10].
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Regarding VLP-based vaccines, about a dozen are currently approved and available
in Europe and the USA. These include Recombivax HB® [11] and Engerix®, both against
hepatitis B [12], and Gardasil® against human papillomavirus (HPV) [13]. Cervarix™
against HPV is relevant to highlight, which contains VLPs produced in insect cells used
in the vaccine market [14,15]. Regulatory agencies have recognized and approved this
production system for its capacity to generate biotechnological products in a safe, effective,
and economical way [16].
During the past few decades, studies on different VLP systems used against important
human diseases—such as Ebola [17], Chikungunya [18], Dengue [19], influenza A [20],
respiratory syncytial virus [21], and Zika [22]—as well as a therapeutic strategy for cancer
of the breast [23], have demonstrated the potential of this technology for the production of
new vaccines. More recently, two of the 64 vaccine projects in progress are based on VLPs,
including those related to the COVID-19 pandemic [24]. This demonstrates the potential
and popularization of the use of VLPs for the development of new vaccines.
In the context of the use of VLPs for the development of vaccines against protozoa,
it was observed that the immunostimulatory property of VLPs with targeted epitopes is
able to induce the production of protective antibodies and a high survival rate of animals
infected with Toxoplasma gondii, the etiologic agent of toxoplasmosis [25,26]. In the context
of malaria, caused by a protozoan of the genus Plasmodium, the presence of lasting immunity
is observed when different vaccine prototypes are produced using antigens associated
with VLPs [27–29].
3. Vaccines to Control Diseases Caused by Trypanosomatids: What Do We Need and
Where Are We?
The main challenge in the development of trypanosomatid vaccines is the adequate
identification of important antigenic candidates for the generation and maintenance of
protective immunity. A second challenge is related to the type and nature of the immune
response induced during the immunization process. However, several studies have been
performed in order to identify potential antigenic candidates for these protozoa, as well
as mechanisms of activation of immunity for the development of vaccines (reviewed in
Reference [30]). Therefore, understanding the cellular and molecular biology of these
protozoa becomes essential to guide new studies in the field of vaccinology to control these
parasitic diseases.
Currently, several tools are being used in the development of vaccines in the con-
text of trypanosomatids, such as immunoinformatic, genomic, and proteomic techniques
that mainly contribute to the identification of new antigenic targets and epitopes of these
parasites [31,32], as well as in the development of various immunization protocols in
experimental models [33–38]. Several proteins and virulence factors are biologically and
structurally shared among protozoa of the trypanosomatid family and therefore could
be used as possible targets for the development of vaccines, such as surface glycopro-
teins [39–41], cysteine proteases [42,43], and metalloproteases [44–46].
Additionally, for the development of vaccines against these trypanosomatids of medi-
cal importance, VLPs are presented as alternatives to induce immunity in a polarized way,
since the mechanisms of resistance and susceptibilities of these infections are related to the
immune response polarization that occurs during a natural infection. Thus, due to their
constitution, they may have the ability to express specific components in amounts compara-
ble to high quantities of these parasites and, furthermore, can present other immunogenic
components, thus allowing a stronger general immune response of the organism [47].
The immune response polarization of the Th1 type (CD4+ T helper cells) is important
for controlling infections caused by trypanosomatids, mainly due to the production of
interferon-γ (IFN-γ) and tumor necrosis factor α (TNF-α). These cytokines induce the acti-
vation of macrophages and, consequently, an increase in the production of reactive oxygen
species, which control the parasitic load during infection. Trypanosomatid parasites have
the ability to reduce Th1-type immune response polarization by enhancing the production
of IL-10 and IL-17 cytokines due to the release of numerous virulence factors [48]. On the
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other hand, the polarization of the Th2-type immune response is responsible for triggering
the polyclonal activation of B cells that result in hypergammaglobulinemia, a phenomenon
characterized by the increased production of antibodies with low specificity and affin-
ity [49]. Therefore, during the parasite–host interaction, trypanosomatids have the ability
to cause immune response polarization, which facilitates the parasitism relationship.
Despite the importance of VLP-based vaccines as a strategy to induce Th1-type im-
mune response polarization, this methodology is still poorly studied in trypanosomatids.
Indeed, only one study was found on Chagas disease [50], and only two used leishmania-
sis [51,52] models. However, to date, no study has been presented in the context of African
trypanosomiasis.
In recent decades, several studies have demonstrated the ability of VLPs to stimulate
the activation of B cells and dendritic cells in the context of MHC class II and, consequently,
the production of cytokines related to the activation of CD4+ T helper cells, which strongly
favors the induction of humoral and cellular immunity [8,53]. In contrast, the presenta-
tion of antigens in the context of MHC class I favors the induction of cellular immunity
mediated by CD8+ T cells and favors the induction of Th1 cells [54]. This phenomenon of
immune response polarization (Th1 versus Th2) is an important opportunity for biomedical
research, since the mechanisms of resistance and susceptibility to infections caused by
trypanosomatids depend on the immune response polarization. The importance of the Th1
immunity profile during infections by T. cruzi and Leishmania spp. is due to the intracellular
forms of these parasites during parasitism in the host [55]. In contrast, T. brucei does
not develop an intracellular phase of infection; however, this protozoan has an antigenic
variation mechanism that favors the chronicity of the infection in the host.
4. Development of Vaccines Based on VLPs: A Checklist
Based on the previous discussion, for the use of VLPs as a strategy for the develop-
ment of vaccines against trypanosomatids, some criteria must be considered, represented
schematically in Figure 2.




Figure 2. Representation of a rational scheme for the development of new vaccines based on virus-like particles (VLPs). 
According to the illustration, there are some essential steps in the checklist: 
1. Should the chosen virus be enveloped or not? Enveloped VLPs are inherited from 
structured viral proteins, thus generating a particle with target antigens integrated 
on the external surface, whereas non-enveloped VLPs are based on the expression of 
one or more necessary viral proteins without inheriting them from a host [56]. Both 
have the additional possibility to integrate antigens [57] and additional adjuvants [7] 
in vaccine formulations. 
2. Which expression system is ideal? It should be noted that, depending on the system, 
there will be limitations such as cost and difficulty in scheduling [58], as well as a 
higher level of purification when faced with contamination from cells [59]. Some 
systems differ from mammalian cells mainly in the protein glycosylation phase [60] 
and do not give rise to a eukaryotic expression environment. The insect cell system 
has come to solve some problems in the production of particulates, as it has charac-
teristics such as a eukaryotic environment, which is required for the glycosylation of 
proteins: this post-translational characteristic is also found in human cells, but the 
cost of their application is higher [61]. In addition, there is malleability in large-scale 
cultivation and the possibility of using it for the simultaneous expression of many 
proteins that facilitate the assembly of VLPs, which requires a structure with a high 
level of safety and a special culture system [58].  
3. The structural modification of the conformational and immunological characteristics 
of the VLP can adjust the relative degree of the immune response for a balanced 
induction of humoral and cellular immunity [62], thereby generating an improved 
candidate capable of redirecting the immune response against specific targets when 
combined with antigens [63]. Thus, this modulates the balance of Th1 and Th2 im-
mune responses to increase the specificity and affinity towards the parasite [48]. 
Therefore, conformational changes and the aggregation of antigens are necessary to 
analyze changes in stability that can compromise the effectiveness of VLP vaccines 
[64]. 
4. Before choosing the antigens, it is necessary to assess the immunological challenges 
found in the parasites that cause Chagas disease, leishmaniasis, and sleeping sick-
ness. They have specific mechanisms of escape from the immune system that end up 
reducing the specific response of the immune system. Based on this assessment, one 
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the external surface, whereas non-enveloped VLPs are based on the expression of one
or more necessary viral proteins without inheriting them from a host [56]. Both have
the additional possibility to integrate antigens [57] and additional adjuvants [7] in
vaccine formulations.
2. Which expression system is ideal? It should be noted that, depending on the system,
there will be limitations such as cost and difficulty in scheduling [58], as well as a
higher level of purification when faced with contamination from cells [59]. Some
systems differ from mammalian cells mainly in the protein glycosylation phase [60]
and do not give rise to a eukaryotic expression environment. The insect cell system has
come to solve some problems in the production of particulates, as it has characteristics
such as a eukaryotic environment, which is required for the glycosylation of proteins:
this post-translational characteristic is also found in human cells, but the cost of their
application is higher [61]. In addition, there is malleability in large-scale cultivation
and the possibility of using it for the simultaneous expression of many proteins that
facilitate the assembly of VLPs, which requires a structure with a high level of safety
and a special culture system [58].
3. The structural modification of the conformational and immunological characteristics
of the VLP can adjust the relative degree of the immune response for a balanced induc-
tion of humoral and cellular immunity [62], thereby generating an improved candidate
capable of redirecting the immune response against specific targets when combined
with antigens [63]. Thus, this modulates the balance of Th1 and Th2 immune re-
sponses to increase the specificity and affinity towards the parasite [48]. Therefore,
conformational changes and the aggregation of antigens are necessary to analyze
changes in stability that can compromise the effectiveness of VLP vaccines [64].
4. Before choosing the antigens, it is necessary to assess the immunological challenges
found in the parasites that cause Chagas disease, leishmaniasis, and sleeping sickness.
They have specific mechanisms of escape from the immune system that end up
reducing the specific response of the immune system. Based on this assessment, one
can then envision a single vaccine for three diseases or specific vaccines for each one,
as VLPs will act as transporters of antigens, with greater security than using soluble
antigens [6]. The applicability of antigens presented in various evolutionary forms of
the protozoan, as well as the attempt to administer immunizations with more than
one antigen to cover all forms of life and increase the antigenic repertoire, must be
considered in studies on T. cruzi, given the genetic variability of this parasite [65]. In
addition, the use of the same antigens for both prophylactic and therapeutic strategies
should be considered, taking into account that prophylactic and therapeutic vaccines
can prevent infection and interfere with the progression of infection, respectively.
For an infected person, a therapeutic vaccine with or without an association with
available drugs can have a significant impact on preventing complications, as has
already been reported for Chagas disease [66].
5. After the production and necessary testing of these particles in isolation and in
association with antigens, in vitro and in vivo tests need to be performed, for example,
endotoxin evaluation [67]. In addition, a basic toxicity assessment must be performed,
according to the WHO guidelines for non-clinical evaluation of vaccines [68]. This
step can also assist in understanding the humoral and cellular immunogenicity of the
isolated particles without antigen association. The choice of adjuvant must include
consideration of the cost–benefit trade-off of co-stimulation, as VLPs can assume the
role of self-adjuvant due to their particulate and multivalent nature, causing efficient
incorporation by antigen-presenting cells (APCs) [69,70].
6. In vivo tests on immunization strategies with these specific antigens and/or with a
chimeric VLP should be performed by firstly establishing the animal model, time, and
doses, characterizing the humoral and cellular immune responses, and importantly,
considering different routes of administration to understand whether this influences
the stability of VLPs [16].
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7. Viral challenges in animals (experimental infection) used in experiments are necessary
to understand, for example, whether the formulation of specific antigens with VLP
technology helps or not in the survival of those infected. After pre-clinical trials
proceed as expected, clinical trials have a significant step in producing results that
confirm a specific, lasting, and harmless response in humans.
Due to the time spent in pre-clinical and clinical trials in the context of safety for
humans, the ideal model at the present moment would be based on known and/or safe
marketed VLPs that could be directed against these three diseases in a formulation system.
Based on the already-known mechanisms of VLP technology and the deep understanding
of the immune response to these parasites, it is still a utopian model of how this strategy
can act in practice.
Here, we propose VLPs that carry antigens of a single individual parasite, thereby
becoming chimeric VLPs. According to some studies, intramuscular application has the
highest efficiency [16], as it penetrates the epidermis to reach deeper layers, with a slow and
gradual release of the formulation. Upon entering the organism, VLPs will be recognized
as foreign bodies by APCs (antigen-presenting cells) that will mediate responses resulting
from the formulation presented. In the ideal model, VLPs in association with antigens are
processed and presented by MHC class II molecules and cause the stimulation of CD4+
T-helper lymphocytes, which will activate B cells and, in turn, stimulate the production of
specific IgG antibodies.
When processed by APCs and presented by MHC class I to CD8+ T cells, a cytotoxic
induction will be observed. Another expected response would be after the recognition
of these antigens by CD4+ T cells: there will be an intensification in the production of
cytokines, such as interferon-γ and TNF-α, which will induce a more aggressive response
by macrophages with a high production of ROS and activate CD8+ T cells [71].
5. Final Considerations and Conclusions
As presented above, VLPs have contributed to the development of new vaccines to
control numerous pathogens of medical importance. Therefore, we believe that this technol-
ogy is promising as a vaccine adjuvant for the manipulation of the immune response during
the induction of immunity, mainly in the context of complex diseases, such as infections
caused by trypanosomatids. Finally, VLP-based vaccines, when properly designed and
formulated, represent a promising platform for chemical or genetic conjugation of parasitic
antigens and the development of multivalent vaccines against protozoa.
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